Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
Other Liabilities
Denali Therapeutics Inc
Other Liabilities Peer Comparison
Competitive Other Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Other Liabilities
$43m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$3.4B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
24%
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$6.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
51%
|
CAGR 10-Years
33%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$1.1B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
18%
|
See Also
What is Denali Therapeutics Inc's Other Liabilities?
Other Liabilities
43m
USD
Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Other Liabilities amounts to 43m USD.
What is Denali Therapeutics Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-18%
Over the last year, the Other Liabilities growth was -17%. The average annual Other Liabilities growth rates for Denali Therapeutics Inc have been -52% over the past three years , -18% over the past five years .